Bypassing the blood-brian barrier using established skull base reconstruction techniques
- PMID: 29204535
- PMCID: PMC5698502
- DOI: 10.1016/j.wjorl.2015.09.001
Bypassing the blood-brian barrier using established skull base reconstruction techniques
Abstract
Background: Neurological disorders represent a profound healthcare problem accounting for 6.3% of the global disease burden. Alzheimer's disease alone is expected to impact over 115 million people worldwide by 2050 with a cost of over $1 trillion per year to the U.S. economy. Despite considerable advances in our understanding of the pathogenesis and natural history of neurological disorders, the development of disease modifying therapies have failed to keep pace. This lack of effective treatments is directly attributable to the presence of the blood-brain and blood-cerebrospinal fluid barriers (BBB and BCSFB) which prevent up to 98% of all potential neuropharmaceutical agents from reaching the central nervous system (CNS). These obstacles have thereby severely limited research and development into novel therapeutic strategies for neurological disease. Current experimental methods to bypass the BBB, including pharmacologic modification and direct transcranial catheter implantation, are expensive, are associated with significant complications, and cannot be feasibly scaled up to meet the chronic needs of a large, aging patient population.
Transmucosal drug delivery: An innovative method of direct CNS drug delivery using heterotopic mucosal grafts was described. This method is based on established endoscopic skull base nasoseptal flap reconstruction techniques. The model has successfully demonstrated CNS delivery of chromophore-tagged molecules 1000 times larger than those typically permitted by the BBB.
Conclusions: This innovative technique represents the first described method of permanently bypassing the blood-brain barrier using purely autologous tissues. This has the potential to dramatically improve the current treatment of neurological disease by providing a safe and chronic transnasaldelivery pathway for high molecular weight neuropharmaceuticals.
Keywords: Blood–brain barrier; Mucosal flap; Skull base reconstruction; Transnasal drug delivery.
Similar articles
-
Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting.Front Pharmacol. 2021 Apr 19;12:660841. doi: 10.3389/fphar.2021.660841. eCollection 2021. Front Pharmacol. 2021. PMID: 33953687 Free PMC article.
-
Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain.PLoS One. 2013 Apr 24;8(4):e61694. doi: 10.1371/journal.pone.0061694. Print 2013. PLoS One. 2013. PMID: 23637885 Free PMC article.
-
The blood-brain barrier and nasal drug delivery to the central nervous system.Am J Rhinol Allergy. 2015 Mar-Apr;29(2):124-7. doi: 10.2500/ajra.2015.29.4149. Am J Rhinol Allergy. 2015. PMID: 25785753 Review.
-
Heterotopic Mucosal Grafting Enables the Delivery of Therapeutic Neuropeptides Across the Blood Brain Barrier.Neurosurgery. 2016 Mar;78(3):448-57; discussion 457. doi: 10.1227/NEU.0000000000001016. Neurosurgery. 2016. PMID: 26352099
-
Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects.Front Pharmacol. 2022 Sep 13;13:979682. doi: 10.3389/fphar.2022.979682. eCollection 2022. Front Pharmacol. 2022. PMID: 36176429 Free PMC article. Review.
Cited by
-
Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting.Front Pharmacol. 2021 Apr 19;12:660841. doi: 10.3389/fphar.2021.660841. eCollection 2021. Front Pharmacol. 2021. PMID: 33953687 Free PMC article.
-
Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors.Front Oncol. 2020 Jun 5;10:739. doi: 10.3389/fonc.2020.00739. eCollection 2020. Front Oncol. 2020. PMID: 32582530 Free PMC article. Review.
-
Blood brain barrier: An overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking.Tissue Barriers. 2015 Dec 15;4(1):e1129476. doi: 10.1080/21688370.2015.1129476. eCollection 2016 Jan-Mar. Tissue Barriers. 2015. PMID: 27141418 Free PMC article. Review.
-
Murine model of minimally invasive nasal depot (MIND) technique for central nervous system delivery of blood-brain barrier-impermeant therapeutics.Lab Anim (NY). 2024 Dec;53(12):363-375. doi: 10.1038/s41684-024-01460-w. Epub 2024 Nov 15. Lab Anim (NY). 2024. PMID: 39548349
-
Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting.PLoS One. 2018 Dec 5;13(12):e0208122. doi: 10.1371/journal.pone.0208122. eCollection 2018. PLoS One. 2018. PMID: 30517163 Free PMC article.
References
-
- World Health Organization. Neurological disorders: public health challenges. Available at: http://www.who.int/mental_health/neurology/neurodiso/en/index.html.
-
- Wimo A., Prince M. Alzheimer's Disease International; London, UK: 2010. World Alzheimer Report 2010. Sci Rep.
-
- Parkinson's Disease: Hope through Research. National Institute of Neurologic Disorders and Stroke; Bethesda, MD: 2006. Sci Rep.
-
- Huse D.M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005;20:1449–1454. - PubMed
-
- De Lau L.M.L., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525–535. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources